KR102364720B1 - 교모세포종 진단용 바이오마커 조성물 - Google Patents
교모세포종 진단용 바이오마커 조성물 Download PDFInfo
- Publication number
- KR102364720B1 KR102364720B1 KR1020200021559A KR20200021559A KR102364720B1 KR 102364720 B1 KR102364720 B1 KR 102364720B1 KR 1020200021559 A KR1020200021559 A KR 1020200021559A KR 20200021559 A KR20200021559 A KR 20200021559A KR 102364720 B1 KR102364720 B1 KR 102364720B1
- Authority
- KR
- South Korea
- Prior art keywords
- glioblastoma
- present
- diagnosing
- expression
- immunoglobulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
도 1B는 U87 세포주의 교모종줄기세포 모사 세포 배양 조건 GBM(glioblastoma)에서 면역글로불린 중쇄가변역(IGHV)의 발현 패턴을 RT-PCR로 확인하여 나타낸 도이다.
도 2는 A172 세포주의 교모종줄기세포 모사 세포 배양 조건 GBM(glioblastoma)에서 면역글로불린 경쇄가변역(IGKV)의 발현 패턴을 RT-PCR로 확인하여 나타낸 도이다.
도 3은 A172 세포주의 교모종줄기세포 모사 세포 배양 조건 GBM(glioblastoma)에서 면역글로불린 경쇄가변역(IGLV)의 발현 패턴을 RT-PCR로 확인하여 나타낸 도이다.
유전자 | 서열 | |
1 | 1_IGHV1_18 | agcacgacaagcagtctccatagtagcgcactggctCAGGTTCAGCTGGTGC |
2 | 2_IGHV1_2 | agcacgacaagcagtctccatagtagcgcactggctCAGGTGCAGCTGGTGC |
3 | 3_IGHV1_24 | agcacgacaagcagtctccatagtagcgcactggctCAGGTCCAGCTGGTAC |
4 | 4_IGHV1_3 | agcacgacaagcagtctccatagtagcgcactggctCAGGTCCAGCTTGTGC |
5 | 5_IGHV1_45 | agcacgacaagcagtctccatagtagcgcactggctCAGATGCAGCTGGTGC |
6 | 6_IGHV1_58 | agcacgacaagcagtctccatagtagcgcactggctCAAATGCAGCTGGTGCA |
7 | 7_IGHV1_69_2 | agcacgacaagcagtctccatagtagcgcactggctGAGGTCCAGCTGGTAC |
8 | 8_IGHV2_26 | agcacgacaagcagtctccatagtagcgcactggctCAGGTCACCTTGAAGGA |
9 | 9_IGHV2_5 | agcacgacaagcagtctccatagtagcgcactggctCAGATCACCTTGAAGGAG |
10 | 10_IGHV2_70 | agcacgacaagcagtctccatagtagcgcactggctCAGGTCACCTTGAGGG |
11 | 11_IGHV3_11 | agcacgacaagcagtctccatagtagcgcactggctCAGGTGCAGCTGGTG |
12 | 12_IGHV3_13 | agcacgacaagcagtctccatagtagcgcactggctGAGGTGCAGCTGGTG |
13 | 13_IGHV3_43 | agcacgacaagcagtctccatagtagcgcactggctGAAGTGCAGCTGGTGG |
14 | 14_IGHV4_28 | agcacgacaagcagtctccatagtagcgcactggctCAGGTACAGCTGCAGG |
15 | 15_IGHV4_34 | agcacgacaagcagtctccatagtagcgcactggctCAGGTGCAGCTACAGC |
16 | 16_IGHV4_4 | agcacgacaagcagtctccatagtagcgcactggctCAGGTGCAGCTGCAG |
17 | 17_IGHV5_10_1 | agcacgacaagcagtctccatagtagcgcactggctGAAGTGCAGCTGGTGC |
18 | 18_IGHV5_51 | agcacgacaagcagtctccatagtagcgcactggctGAGGTGCAGCTGGTG |
19 | 19_IGHV6_1 | agcacgacaagcagtctccatagtagcgcactggctCAGGTACAGCTGCAGC |
20 | 20_IGHV7_4_1 | agcacgacaagcagtctccatagtagcgcactggctCAGGTGCAGCTGGTGC |
21 | 21_IGKV1_12 | atggagactgcttgtcgtgctagtagcgcactggctGACATCCAGATGACCCA |
22 | 22_IGKV1_13 | atggagactgcttgtcgtgctagtagcgcactggctGCCATCCAGTTGACCCA |
23 | 23_IGKV1_6 | atggagactgcttgtcgtgctagtagcgcactggctGCCATCCAGATGACCCA |
24 | 24_IGKV1_8 | atggagactgcttgtcgtgctagtagcgcactggctGCCATCCGGATGACCC |
25 | 25_IGKV1_9 | atggagactgcttgtcgtgctagtagcgcactggctGACATCCAGTTGACCCA |
26 | 26_IGKV1D_17 | atggagactgcttgtcgtgctagtagcgcactggctAACATCCAGATGACCCAGT |
27 | 27_IGKV1D_8 | atggagactgcttgtcgtgctagtagcgcactggctGCCATCTGGATGACCCA |
28 | 28_IGKV2_24 | atggagactgcttgtcgtgctagtagcgcactggctGATATTGTGATGACCCAGAC |
29 | 29_IGKV2_28 | atggagactgcttgtcgtgctagtagcgcactggctGATATTGTGATGACTCAGTC |
30 | 30_IGKV2_30 | atggagactgcttgtcgtgctagtagcgcactggctGATGTTGTGATGACTCAGTC |
31 | 31_IGKV3_11 | atggagactgcttgtcgtgctagtagcgcactggctGAAATTGTGTTGACACAGTC |
32 | 32_IGKV3_15 | atggagactgcttgtcgtgctagtagcgcactggctGAAATAGTGATGACGCAGTC |
33 | 33_IGKV3_20 | atggagactgcttgtcgtgctagtagcgcactggctGAAATTGTGTTGACGCAGTC |
34 | 34_IGKV3D_7 | atggagactgcttgtcgtgctagtagcgcactggctGAAATTGTAATGACACAGTCTC |
35 | 35_IGKV4_1 | atggagactgcttgtcgtgctagtagcgcactggctGACATCGTGATGACCCA |
36 | 36_IGKV5_2 | atggagactgcttgtcgtgctagtagcgcactggctGAAACGACACTCACGCA |
37 | 37_IGKV6_21 | atggagactgcttgtcgtgctagtagcgcactggctGAAATTGTGCTGACTCAGTC |
38 | 38_IGKV6D_41 | atggagactgcttgtcgtgctagtagcgcactggctGATGTTGTGATGACACAGTC |
39 | 39_IGLV1_36 | atggagactgcttgtcgtgctagtagcgcactggctCAGTCTGTGCTGACTCA |
40 | 40_IGLV1_40 | atggagactgcttgtcgtgctagtagcgcactggctCAGTCTGTGCTGACGC |
41 | 41_IGLV1_51 | atggagactgcttgtcgtgctagtagcgcactggctCAGTCTGTGTTGACGCA |
42 | 42_IGLV2_11 | atggagactgcttgtcgtgctagtagcgcactggctCAGTCTGCCCTGACTC |
43 | 43_IGLV2_33 | atggagactgcttgtcgtgctagtagcgcactggctCAATCTGCCCTGACTCA |
44 | 44_IGLV3_1 | atggagactgcttgtcgtgctagtagcgcactggctTCCTATGAGCTGACTCAG |
45 | 45_IGLV3_10 | atggagactgcttgtcgtgctagtagcgcactggctTCCTATGAGCTGACACAG |
46 | 46_IGLV3_19 | atggagactgcttgtcgtgctagtagcgcactggctTCTTCTGAGCTGACTCAG |
47 | 47_IGLV3_21 | atggagactgcttgtcgtgctagtagcgcactggctTCCTATGTGCTGACTCAG |
48 | 48_IGLV3_32 | atggagactgcttgtcgtgctagtagcgcactggctTCCTCTGGGCCAACTC |
49 | 49_IGLV4_3 | atggagactgcttgtcgtgctagtagcgcactggctCTGCCTGTGCTGACTC |
50 | 50_IGLV4_60 | atggagactgcttgtcgtgctagtagcgcactggctCAGCCTGTGCTGACTCA |
51 | 51_IGLV4_69 | atggagactgcttgtcgtgctagtagcgcactggctCAGCTTGTGCTGACTCAA |
52 | 52_IGLV5_37 | atggagactgcttgtcgtgctagtagcgcactggctCAGCCTGTGCTGACTC |
53 | 53_IGLV5_45 | atggagactgcttgtcgtgctagtagcgcactggctCAGGCTGTGCTGACTC |
54 | 54_IGLV6_57 | atggagactgcttgtcgtgctagtagcgcactggctAATTTTATGCTGACTCAGCC |
55 | 55_IGLV7_43 | atggagactgcttgtcgtgctagtagcgcactggctCAGACTGTGGTGACTCA |
56 | 56_IGLV7_46 | atggagactgcttgtcgtgctagtagcgcactggctCAGGCTGTGGTGACTC |
57 | 57_IGLV8_61 | atggagactgcttgtcgtgctagtagcgcactggctCAGACTGTGGTGACCC |
58 | 58_IGLV10_54 | atggagactgcttgtcgtgctagtagcgcactggctCAGGCAGGGCTGACTC |
59 | 59_IGLV11_55 | atggagactgcttgtcgtgctagtagcgcactggctCGGCCCGTGCTGACTC |
60 | 60_IgG_R_NP | AGGGYGCCAGGGGGAAGAC |
61 | 61_IgA_R_NP | CGGGAAGACCTTGGGGCTGG |
62 | 62_IgM_R_NP | CACAGGAGACGAGGGGGAAA |
63 | 63_IgKC_R_NP | GATGAAGACAGATGGTGCAG |
64 | 64_IgLC_R_NP | TCCTCAGAGGAGGGYGGGAA |
Claims (8)
- IGHV, IGKV 및 IGLV 유전자를 포함하는 교모세포종 진단용 바이오마커 조성물.
- IGHV, IGKV 및 IGLV 유전자의 발현 수준을 측정할 수 있는 제제를 포함하는 교모세포종 진단용 조성물.
- 제2항에 있어서,
상기 제제는 상기 IGHV, IGKV 및 IGLV 유전자를 코딩하는 핵산 서열 또는 이에 상보적인 서열에 혼성화 될 수 있는 프로브(probe) 또는 프라이머(primer)인 것을 특징으로 하는 교모세포종 진단용 조성물. - 제2항에 있어서,
상기 유전자가 정상 세포에서의 유전자 발현양과 비교하여 고발현되거나 저발현되는 경우, 교모세포종인 것으로 진단하는 것인, 교모세포종 진단용 조성물. - IGHV, IGKV 및 IGLV 유전자의 발현을 측정하는 단계를 포함하는, 교모세포종 진단을 위한 정보 제공 방법.
- 제5항에 있어서,
상기 유전자의 양이 정상세포와 비교하여 고발현 또는 저발현 되는 경우, 교모세포종을 진단하는 것인, 교모세포종 진단을 위한 정보 제공 방법. - IGHV, IGKV 및 IGLV 유전자의 발현수준을 측정하는 제제;를 포함하는 교모세포종 진단용 키트.
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200021559A KR102364720B1 (ko) | 2020-02-21 | 2020-02-21 | 교모세포종 진단용 바이오마커 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200021559A KR102364720B1 (ko) | 2020-02-21 | 2020-02-21 | 교모세포종 진단용 바이오마커 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210106718A KR20210106718A (ko) | 2021-08-31 |
KR102364720B1 true KR102364720B1 (ko) | 2022-02-18 |
Family
ID=77489460
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200021559A Active KR102364720B1 (ko) | 2020-02-21 | 2020-02-21 | 교모세포종 진단용 바이오마커 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102364720B1 (ko) |
-
2020
- 2020-02-21 KR KR1020200021559A patent/KR102364720B1/ko active Active
Non-Patent Citations (2)
Title |
---|
Eur Rev Med Pharmacol Sci, 21(14): 3207-3211 |
Neurochem Int, 71: 1-7 |
Also Published As
Publication number | Publication date |
---|---|
KR20210106718A (ko) | 2021-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102719587B1 (ko) | 아데노-관련 바이러스 생산을 위한 포유동물 세포 | |
KR102630357B1 (ko) | 단백질 발현이 어려운 다중-부위 ssi 세포 | |
AU2017267184B2 (en) | Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy | |
AU2013358958B2 (en) | Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same | |
KR102729669B1 (ko) | 다중화 게놈 편집 | |
KR101234281B1 (ko) | 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제 | |
AU2016364667A1 (en) | Materials and methods for treatment of Alpha-1 antitrypsin deficiency | |
AU2016376191A1 (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
JP2003088388A (ja) | 新規な全長cDNA | |
JP2003135075A (ja) | 新規な全長cDNA | |
EP1165784A2 (en) | Nucleic acids including open reading frames encoding polypeptides; "orfx" | |
WO1995014772A1 (fr) | Signature genique | |
CN107223159A (zh) | 源自特定细胞类型的dna的检测及相关方法 | |
KR20180093902A (ko) | 태아와 임신 여성간에 상이하게 메틸화된 디엔에이 영역을 이용한 태아 염색체 이수성의 검출 | |
AU2017289886A1 (en) | Engineered parasites for delivering protein to the central nervous system (CNS) | |
KR20220024184A (ko) | 대장암의 검출 | |
KR20220025749A (ko) | 대장암의 검출 | |
KR20220054401A (ko) | 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물 | |
KR102777514B1 (ko) | 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체 | |
KR20040065524A (ko) | 백혈병을 검사 및 치료하는 방법 | |
KR20110110030A (ko) | 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트 | |
KR101978399B1 (ko) | 자궁내막증에 대한 진단 마커로서의 돌연변이 유전자 및 이의 용도 | |
JP2002017375A (ja) | 全長cDNA合成用プライマー、およびその用途 | |
KR102477906B1 (ko) | 유도만능 줄기세포 분화 특이적 lncRNA, 및 이의 용도 | |
KR20120106721A (ko) | 신경발생 및 이의 조절에 관련된 유전자, 방법, 그리고 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20200221 |
|
PA0201 | Request for examination | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210419 Patent event code: PE09021S01D |
|
AMND | Amendment | ||
PG1501 | Laying open of application | ||
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20211028 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20210419 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
X091 | Application refused [patent] | ||
AMND | Amendment | ||
PX0901 | Re-examination |
Patent event code: PX09011S01I Patent event date: 20211028 Comment text: Decision to Refuse Application Patent event code: PX09012R01I Patent event date: 20210618 Comment text: Amendment to Specification, etc. |
|
PX0701 | Decision of registration after re-examination |
Patent event date: 20211220 Comment text: Decision to Grant Registration Patent event code: PX07013S01D Patent event date: 20211122 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I Patent event date: 20211028 Comment text: Decision to Refuse Application Patent event code: PX07011S01I Patent event date: 20210618 Comment text: Amendment to Specification, etc. Patent event code: PX07012R01I |
|
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220215 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20220215 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration |